Terug
Ook genoteerd als
TRUMF
OTC
Dagbereik
€ 13,10
€ 13,50
52-Weeksbereik
€ 12,15
€ 20,12
Volume
53.182
50D / 200D Gem.
€ 13,27
/
€ 15,85
Vorige Slotkoers
€ 12,55
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,2 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 8,7 | 3,7 |
| Net Margin % | 11,3 | 3,8 |
| Rev Growth 5Y % | 14,0 | 10,0 |
| D/E | 0,1 | 0,2 |
Belangrijkste Punten
Revenue grew 13,98% annually over 5 years — strong growth
Debt/Equity of 0,13 — conservative balance sheet
Generating 128,44B in free cash flow
P/E of 0,17 — trading at a low valuation
Cash machine — converts 109,80% of earnings into free cash flow
Capital efficient — spends only 7,95% of revenue on capex
Groei
Revenue Growth (5Y)
13,98%
Revenue (1Y)12,40%
Earnings (1Y)9,97%
FCF Growth (3Y)68,27%
Kwaliteit
Return on Equity
8,68%
ROIC7,66%
Net Margin11,29%
Op. Margin15,22%
Veiligheid
Debt / Equity
0,13
Current Ratio3,00
Interest Coverage25,24
Waardering
P/E Ratio
0,17
P/B Ratio0,01
EV/EBITDA-0,17
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 12,40% | Revenue Growth (3Y) | 12,40% |
| Earnings Growth (1Y) | 9,97% | Earnings Growth (3Y) | 14,44% |
| Revenue Growth (5Y) | 13,98% | Earnings Growth (5Y) | 10,92% |
| Profitability | |||
| Revenue (TTM) | 1,04T | Net Income (TTM) | 116,98B |
| ROE | 8,68% | ROA | 6,40% |
| Gross Margin | 54,11% | Operating Margin | 15,22% |
| Net Margin | 11,29% | Free Cash Flow (TTM) | 128,44B |
| ROIC | 7,66% | FCF Growth (3Y) | 68,27% |
| Safety | |||
| Debt / Equity | 0,13 | Current Ratio | 3,00 |
| Interest Coverage | 25,24 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 0,17 | P/B Ratio | 0,01 |
| P/S Ratio | 0,02 | PEG Ratio | 3,39 |
| EV/EBITDA | -0,17 | Dividend Yield | 0,01% |
| Market Cap | 19,56B | Enterprise Value | -27,47B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,04T | 921,86B | 820,21B | 703,30B | 613,84B |
| Net Income | 116,98B | 106,37B | 89,33B | 88,81B | 77,27B |
| EPS (Diluted) | 78,99 | 71,47 | 59,48 | 58,69 | 51,05 |
| Gross Profit | 560,67B | 479,18B | 417,37B | 369,34B | 326,62B |
| Operating Income | 157,67B | 140,10B | 117,33B | 115,96B | 98,39B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,83T | 1,83T | 1,60T | 1,47T | 1,35T |
| Total Liabilities | 459,86B | 504,31B | 491,16B | 461,38B | 494,53B |
| Shareholders' Equity | 1,37T | 1,33T | 1,11T | 1,01T | 856,66B |
| Total Debt | 174,84B | 268,55B | 231,94B | 259,01B | 293,08B |
| Cash & Equivalents | 221,87B | 204,88B | 187,32B | 205,25B | 200,77B |
| Current Assets | 723,50B | 722,12B | 611,40B | 558,71B | 523,97B |
| Current Liabilities | 240,97B | 379,15B | 218,00B | 177,72B | 211,37B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026